Edmond DE Rothschild Holding S.A. Buys New Stake in DENTSPLY SIRONA Inc. $XRAY

Edmond DE Rothschild Holding S.A. purchased a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,503,300 shares of the medical instruments supplier’s stock, valued at approximately $47,780,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in DENTSPLY SIRONA in the second quarter valued at $283,405,000. Southpoint Capital Advisors LP purchased a new stake in shares of DENTSPLY SIRONA during the 1st quarter worth about $116,000,000. AQR Capital Management LLC boosted its stake in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Armistice Capital LLC grew its position in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the period. Institutional investors and hedge funds own 95.70% of the company’s stock.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian P. Mckeon bought 10,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were acquired at an average cost of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Brian T. Gladden bought 9,985 shares of the stock in a transaction dated Monday, June 15th. The shares were bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director owned 61,849 shares in the company, valued at approximately $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 35,160 shares of company stock valued at $351,179. Corporate insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on XRAY shares. Mizuho reduced their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. UBS Group dropped their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Barrington Research set a $15.00 price objective on DENTSPLY SIRONA in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. Finally, Barclays decreased their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.38.

DENTSPLY SIRONA Trading Down 0.7%

Shares of XRAY stock opened at $11.03 on Thursday. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.40 and a fifty-two week high of $14.86. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. The stock’s fifty day moving average is $11.99 and its two-hundred day moving average is $11.82. The firm has a market capitalization of $2.20 billion, a P/E ratio of -4.01, a PEG ratio of 1.40 and a beta of 0.85.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts expect that DENTSPLY SIRONA Inc. will post 1.41 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.